GSGeorge F. Santos

George F. Santos

*This is an algorithmically generated author record based on publicly available information.

George F. Santos has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • John Donnelly

    Novartis Vaccines and Diagnostics, 350 Massachusetts Avenue, Cambridge, Massachusetts 02139

    2 shared publications
  • Marzia Giuliani

    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy

    2 shared publications
  • Ann E. Herman

    Immunology, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121

    1 shared publication
  • Bill Wacknov

    Immunology, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121

    1 shared publication
  • Jeanette Adu-Bobie

    Novartis Vaccines, 350 Massachusetts Ave., Cambridge, Massachusetts 02139,1 Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy,2 Novartis Vaccines, 4560 Horton St., Emeryville, California 946083

    1 shared publication
  • Jeff Janes

    Informatics, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121

    1 shared publication

Latest Publications

  • Open Access

    Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis

    by Puiying A. Mak, George F. Santos, Kelly-Anne Masterman, Jeff Janes, Bill Wacknov, Kay Vienken, Marzia Giuliani, Ann E. Herman, Michael Cooke, M. Lamine Mbow, et al.

    Complement-mediated bactericidal activity has long been regarded as the serological correlate of protective immunity againstNeisseria meningitidis. This was affirmed in 2005 at a WHO-sponsored meningococcal serology standardization workshop. The assay currently employed by most laboratories involves determining surviving bacterial colony counts on agar as a readout which is labor-intensive, time-consuming, and not amendable to rapid data analysis for clinical trials. Consequently, there is an acute need to develop a sensitive, high-throughput bactericidal assay to enable a rapid and robust assessment of the effectiveness of vaccine candidates. To this end, we have developed an automated, kinetic assay based on the fluorescent respiration product of resazurin which reduces assay volume, shortens assay time, and facilitates automation of data analysis. We demonstrate proof of concept for applicability of this high-throughput system with multiple meningococcal strains and utilizing different lots of human complement. The assay is robust and highly reproducible. Titers obtained by the fluorescence readout method are strongly correlated with the data obtained using the conventional, agar plate-based assay. These results demonstrate that the detection of bacteria that have survived the bactericidal reaction by measuring metabolic activity using a fluorescent dye as an alternative readout is a promising approach for the development of a high-throughput bactericidal assay.


  • Investigation on the Effect of Immune Selection on Resistance to Bactericidal Antibodies to Group B Meningococci In Vitro

    by George F. Santos, Marzia Giuliani, Laura Santini, Jeanette Adu-Bobie, Mariagrazia Pizza, Rino Rappuoli, William Wacknov, John Donnelly

    The induction of resistance by immune selective pressure to bactericidal antibodies from humans immunized with Novartis recombinant meningococcal group B vaccines was assessed. Serum bactericidal antibody titers against selected bacteria were within assay variability through a selection event frequency of 1 in 10 −5 . No change in antigen expression was observed by Western blotting.